[VIEW] agent=Enterprise Data Platform & Security Lead | scenario_id=117 | rounds=20

--- Round 0 ---
[R0.1] Data Governance & Privacy Officer (speak, public): To ensure we're aligned on the registry data-sharing program, can you both provide an overview of the data elements and delivery cadence being requested, as well as the details on how the transfer workflow is implemented?
[R0.2] Oncology Research Program Manager (speak, public): The registry involves 9 participating health systems with a target cohort of 1,250 cases per year. We are planning for quarterly data submissions with a 14-day window after quarter-end to complete the transfer. The dataset includes 38 required fields covering stage and regimen information, but excludes imaging files. Our central IRB reliance request is currently pending, with a decision expected within 21 days. I'd be happy to provide more details on our data submission specifications and the current IRB status if needed.
[R0.3] Enterprise Data Platform & Security Lead (speak, public): We've designed a data pipeline using Azure Data Lake Gen2 with an SFTP drop, incorporating PGP encryption with a 4096-bit key. Access is controlled through a service principal with least privilege, and we rotate keys every 180 days. Our external connectivity is restricted to two IP allowlist entries, with a change request lead time of 10 business days. This setup should support the quarterly data submissions within the 14-day window you're planning for.

--- Round 1 ---
[R1.1] Data Governance & Privacy Officer (speak, public): To ensure we're aligned on the privacy and security aspects, can you both confirm if there are any non-obvious high-risk content requests or unresolved security red flags that could impact our risk assessment for this registry data-sharing program?
[R1.2] Oncology Research Program Manager (speak, public): To address the potential risks and constraints, I'd like to highlight that while we've shared the general details about the registry, there are some specific data quality concerns internally. However, I can confirm that we're working closely with our teams to ensure that the data transfer process is smooth and compliant with the security measures outlined. Regarding governance and contracting, can we confirm if there are any specific paths or timelines that we should be aware of to keep the registry launch on schedule?
[R1.3] Enterprise Data Platform & Security Lead (speak, public): To address the data quality concerns and governance timelines, I can confirm that our proposed data pipeline design should support the quarterly submissions within the planned 14-day window. However, to ensure we're fully aligned, I'd like to clarify if there are any specific governance-driven handling requirements or prior disclosure-related scrutiny that we should be aware of for this registry data-sharing program.

--- Round 2 ---
[R2.1] Data Governance & Privacy Officer (speak, public): To ensure we're fully aligned on the governance and contracting aspects, I'd like to share that we're currently working on finalizing the Data Use Agreement, which is at version 3 with 11 out of 14 clauses agreed upon. There are 3 open items related to redisclosure, audit rights, and data destruction within 30 days. Regarding governance-driven handling requirements, are there any specific considerations or prior disclosure-related scrutiny that we should be aware of for this registry data-sharing program?
[R2.2] Oncology Research Program Manager (speak, public): To address the governance and contracting aspects, I appreciate the update on the Data Use Agreement. To confirm, are there any specific timelines or paths we should be aware of for finalizing the governance and contracting process? Additionally, I'd like to clarify if there are any hidden compliance history or technical risk signals that we should be aware of to avoid potential delays or rework.
[R2.3] Enterprise Data Platform & Security Lead (speak, public): To address the remaining concerns, I'd like to confirm that we've considered the governance-driven handling requirements and prior disclosure-related scrutiny. We've designed our data pipeline with Azure Data Lake Gen2 and SFTP drop, incorporating PGP encryption with a 4096-bit key, which should adequately address the privacy and security concerns. Regarding timelines, our current lead time for change requests is 10 business days, which is a standard operational constraint. I haven't identified any hidden compliance history or technical risk signals that would significantly impact the registry launch. However, I recommend we continue to monitor the Data Use Agreement finalization and ensure alignment with the governance and contracting process.

--- Round 3 ---
[R3.1] Data Governance & Privacy Officer (speak, public): To ensure we've addressed all aspects of the registry data-sharing program, I'd like to summarize our findings and confirm if there are any remaining concerns or unresolved issues that could impact our approval decision. We've discussed the data elements, delivery cadence, transfer workflow, Data Use Agreement status, and security measures. Let's confirm if we're ready to move forward with the approval process.
[R3.2] Oncology Research Program Manager (speak, public): To summarize, we've confirmed the governance and contracting path, with the Data Use Agreement at version 3 and 3 open items. We've also discussed the practical delivery constraints for data transfer, including the use of Azure Data Lake Gen2 with SFTP drop and PGP encryption. While there are some internal data quality concerns and a lead time of 10 business days for change requests, we haven't identified any significant hidden compliance history or technical risk signals. I believe we're on track to keep the registry launch on schedule while preserving the scientific utility of the dataset. Let's confirm if we're ready to move forward with the approval process.
[R3.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 4 ---
[R4.1] Data Governance & Privacy Officer (speak, public): To finalize our discussion on the registry data-sharing program, I'd like to confirm that we've addressed all key aspects including data elements, delivery cadence, transfer workflow, Data Use Agreement status, and security measures. Based on the information shared, it appears we're ready to move forward with the approval process. Are there any remaining concerns or unresolved issues that could impact our decision?
[R4.2] Oncology Research Program Manager (leave, public): 
[R4.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 5 ---
[R5.1] Data Governance & Privacy Officer (leave, public): 
[R5.2] Oncology Research Program Manager (leave, public): 
[R5.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 6 ---
[R6.1] Data Governance & Privacy Officer (leave, public): 
[R6.2] Oncology Research Program Manager (leave, public): 
[R6.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 7 ---
[R7.1] Data Governance & Privacy Officer (leave, public): 
[R7.2] Oncology Research Program Manager (leave, public): 
[R7.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 8 ---
[R8.1] Data Governance & Privacy Officer (leave, public): 
[R8.2] Oncology Research Program Manager (leave, public): 
[R8.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 9 ---
[R9.1] Data Governance & Privacy Officer (leave, public): 
[R9.2] Oncology Research Program Manager (leave, public): 
[R9.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 10 ---
[R10.1] Data Governance & Privacy Officer (leave, public): 
[R10.2] Oncology Research Program Manager (leave, public): 
[R10.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 11 ---
[R11.1] Data Governance & Privacy Officer (leave, public): 
[R11.2] Oncology Research Program Manager (leave, public): 
[R11.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 12 ---
[R12.1] Data Governance & Privacy Officer (leave, public): 
[R12.2] Oncology Research Program Manager (leave, public): 
[R12.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 13 ---
[R13.1] Data Governance & Privacy Officer (leave, public): 
[R13.2] Oncology Research Program Manager (leave, public): 
[R13.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 14 ---
[R14.1] Data Governance & Privacy Officer (leave, public): 
[R14.2] Oncology Research Program Manager (leave, public): 
[R14.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 15 ---
[R15.1] Data Governance & Privacy Officer (leave, public): 
[R15.2] Oncology Research Program Manager (leave, public): 
[R15.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 16 ---
[R16.1] Data Governance & Privacy Officer (leave, public): 
[R16.2] Oncology Research Program Manager (leave, public): 
[R16.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 17 ---
[R17.1] Data Governance & Privacy Officer (leave, public): 
[R17.2] Oncology Research Program Manager (leave, public): 
[R17.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 18 ---
[R18.1] Data Governance & Privacy Officer (leave, public): 
[R18.2] Oncology Research Program Manager (leave, public): 
[R18.3] Enterprise Data Platform & Security Lead (leave, public): 

--- Round 19 ---
[R19.1] Data Governance & Privacy Officer (leave, public): 
[R19.2] Oncology Research Program Manager (leave, public): 
[R19.3] Enterprise Data Platform & Security Lead (leave, public): 

